Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

BPH

Therapeutic area intelligence for BPH with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 1

Companies

Aurobindo Pharma →

Assets

Recent signals(3)

RegulatoryAugust 5, 2026

FDA Accepts Supplement Application for Tamsulosin Hydrochloride by Synthon BV

The FDA has accepted a supplemental application for Tamsulosin Hydrochloride submitted by Synthon BV.

RegulatoryJuly 9, 2026

Aurobindo Pharma submits SUPPL for Alfuzosin Hydrochloride (ANDA079060)

Aurobindo Pharma has submitted a supplemental application for Alfuzosin Hydrochloride under ANDA079060.

ClinicalJune 22, 2026

Trial Compares Tamsulosin Dose Escalation vs. Silodosin Switch in BPH-Related Urinary Retention

A randomized controlled trial is assessing the efficacy of tamsulosin dose escalation versus switching to silodosin in men with acute urinary retention due to BPH.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.